Skip to main content
. 2017 Nov 27;8(65):109289–109300. doi: 10.18632/oncotarget.22672

Figure 1. Expression of APRIL, BCMA and TACI in lung specimens.

Figure 1

(A) Immunohistochemistry in cancerous tissue samples, showing abnormal expression of APRIL, BCMA, TACI and negative control (same tissue but without primary antibody). Tissue sections from 3 subtypes of NSCLC were stained with these three antibodies respectively or without primary antibody. Brown staining indicates immunopositive cells. (B) Survival curves were plotted for NSCLC patients.